205 related articles for article (PubMed ID: 22434170)
1. [Current perspectives in the treatment of multiple myeloma - news and views].
Knop S
Dtsch Med Wochenschr; 2012 Mar; 137(13):636-9. PubMed ID: 22434170
[No Abstract] [Full Text] [Related]
2. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
4. Further progress in the treatment of multiple myeloma?
Malik PS; Kumar L
Natl Med J India; 2009; 22(1):25-7. PubMed ID: 19761157
[No Abstract] [Full Text] [Related]
5. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
6. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib in multiple myeloma.
Vandenbroucke JP; Kroep JR
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
[No Abstract] [Full Text] [Related]
9. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
10. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
11. [Treatment for multiple myeloma: current status and future strategy in Japan].
Iida S
Rinsho Ketsueki; 2008 Oct; 49(10):1368-73. PubMed ID: 18833921
[No Abstract] [Full Text] [Related]
12. Allografting or autografting for myeloma.
van Rhee F; Crowley J; Barlogie B
N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17582078
[No Abstract] [Full Text] [Related]
13. Bortezomib in multiple myeloma.
Cecchi M; Caccese E; Messori A
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
[No Abstract] [Full Text] [Related]
14. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
16. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
Moreau P; Hulin C; Marit G; Caillot D; Facon T; Lenain P; Berthou C; Pégourié B; Stoppa AM; Casassus P; Michallet M; Benboubker L; Maisonneuve H; Doyen C; Leyvraz S; Mathiot C; Avet-Loiseau H; Attal M; Harousseau JL;
Leukemia; 2010 Jun; 24(6):1233-5. PubMed ID: 20428201
[No Abstract] [Full Text] [Related]
17. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
18. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
19. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]